RLYB
Rallybio Corporation [RLYB] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RLYB Stock Summary
Top 10 Correlated Stocks
RLYB
In the News
RLYB Financial details
Company Rating
Neutral
Market Cap
83.19M
Income
-72.91M
Revenue
0
Book val./share
2.61
Cash/share
2.7
Dividend
-
Dividend %
-
Employees
43
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-1.18
Forward P/E
-
PEG
0.85
P/S
-
P/B
0.65
P/C
0.64
P/FCF
-1.19
Quick Ratio
12.91
Current Ratio
14.08
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-1.8
EPS next Y
-
EPS next Q
-
EPS this Y
-11.96%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
11.11%
-
-
-
-
SMA20
-
SMA50
100%
SMA100
-
Inst Own
65.56%
Inst Trans
0.79%
ROA
-51%
ROE
-46%
ROC
-0.61%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.225-9.14
52W High
-80.78%
52W Low
+73%
RSI
49
Rel Volume
0.17
Avg Volume
1.55M
Volume
260.26K
Perf Week
-41.95%
Perf Month
-7.49%
Perf Quarter
-56.97%
Perf Half Y
-56.31%
-
-
-
-
Beta
-1.641
-
-
Volatility
0.17%, 0.27%
Prev Close
3.59%
Price
1.73
Change
-3.89%
RLYB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.55 | -0.78 | -1.46 | -2.09 | -1.84 | |
| Operating cash flow per share | -0.47 | -0.69 | -1.42 | -1.8 | -1.49 | |
| Free cash flow per share | -0.47 | -0.69 | -1.43 | -1.8 | -1.49 | |
| Cash per share | 0.61 | 4.36 | 5.46 | 5.31 | 2.72 | |
| Book value per share | -0.64 | -1.46 | 5.47 | 5.32 | 2.63 | |
| Tangible book value per share | -0.63 | -1.43 | 5.47 | 5.32 | 2.63 | |
| Share holders equity per share | -0.64 | -1.46 | 5.47 | 5.32 | 2.63 | |
| Interest debt per share | 0 | 0 | 0 | -0.05 | 0.01 | |
| Market cap | 453.03M | 453.03M | 306.52M | 209.07M | 96.67M | |
| Enterprise value | 433.57M | 312.8M | 131.19M | 152.66M | 72.57M | |
| P/E ratio | -25.7 | -18.18 | -6.52 | -3.14 | -1.3 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -30.15 | -20.56 | -6.73 | -3.65 | -1.6 | |
| PFCF ratio | -29.78 | -20.43 | -6.68 | -3.65 | -1.6 | |
| P/B Ratio | -22.03 | -9.64 | 1.75 | 1.23 | 0.91 | |
| PTB ratio | -22.03 | -9.64 | 1.75 | 1.23 | 0.91 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -24.93 | -12.6 | -2.88 | -2.33 | -0.92 | |
| EV to operating cash flow | -28.85 | -14.19 | -2.88 | -2.67 | -1.2 | |
| EV to free cash flow | -28.5 | -14.11 | -2.86 | -2.66 | -1.2 | |
| Earnings yield | -0.04 | -0.06 | -0.15 | -0.32 | -0.77 | |
| Free cash flow yield | -0.03 | -0.05 | -0.15 | -0.27 | -0.62 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 1.12 | 5.65 | 3.85 | 0.86 | 0.31 | |
| Current ratio | 5.5 | 24.18 | 27.61 | 16.71 | 12.39 | |
| Interest coverage | -452.36 | -516.39 | -4.56K | 29.45 | 0 | |
| Income quality | 0.86 | 0.83 | 0.97 | 0.86 | 0.81 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -7.23 | -2.21 | -3.06 | -0.32 | -0.08 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.81 | 5.05 | 13.41 | 15.82 | 10.44 | |
| ROIC | 0.87 | 0.54 | -0.27 | -0.4 | -0.76 | |
| Return on tangible assets | -0.82 | -0.18 | -0.26 | -0.37 | -0.64 | |
| Graham Net | -0.7 | -1.48 | 5.25 | 4.96 | 2.48 | |
| Working capital | 17.11M | 135.42M | 174.32M | 168.75M | 105.53M | |
| Tangible asset value | -20.28M | -46.02M | 175.6M | 169.32M | 106.18M | |
| Net current asset value | -20.97M | -46.62M | 174.29M | 168.38M | 105.35M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 1.22M | 1.09M | 858.5K | 1.05M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 11.87K | 9.29K | 2.02K | 2.43K | 2.37K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.03 | 0.04 | 0.18 | 0.15 | 0.15 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.86 | 0.53 | -0.27 | -0.39 | -0.7 | |
| Capex per share | -0.01 | 0 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.43 | -0.39 | -0.46 | -0.45 | -0.5 | |
| Operating cash flow per share | -0.43 | -0.47 | -0.33 | -0.41 | -0.29 | |
| Free cash flow per share | -0.43 | -0.45 | -0.33 | -0.41 | -0.29 | |
| Cash per share | 4.76 | 3.74 | 3.41 | 2.99 | 2.7 | |
| Book value per share | 4.77 | 3.86 | 3.45 | 3.05 | 2.61 | |
| Tangible book value per share | 4.77 | 3.86 | 3.45 | 3.05 | 2.61 | |
| Share holders equity per share | 4.77 | 3.86 | 3.45 | 3.05 | 2.61 | |
| Interest debt per share | -0.01 | -0.03 | 0.01 | 0.01 | 0.01 | |
| Market cap | 233.34M | 229.82M | 228.46M | 136.59M | 97.13M | |
| Enterprise value | 176.94M | 190.82M | 196.38M | 117.86M | 73.03M | |
| P/E ratio | -3.86 | -3.67 | -3.07 | -1.86 | -1.2 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -15.29 | -12.25 | -17.07 | -8.29 | -8.34 | |
| PFCF ratio | -15.29 | -12.76 | -17.07 | -8.29 | -8.33 | |
| P/B Ratio | 1.38 | 1.48 | 1.64 | 1.11 | 0.91 | |
| PTB ratio | 1.38 | 1.48 | 1.64 | 1.11 | 0.91 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -11.07 | -10.39 | -9.78 | -6.09 | -3.46 | |
| EV to operating cash flow | -11.59 | -10.17 | -14.67 | -7.16 | -6.27 | |
| EV to free cash flow | -11.59 | -10.59 | -14.67 | -7.16 | -6.26 | |
| Earnings yield | -0.06 | -0.07 | -0.08 | -0.13 | -0.21 | |
| Free cash flow yield | -0.07 | -0.08 | -0.06 | -0.12 | -0.12 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 3.53 | 2.12 | 1.6 | 0.97 | 1.14 | |
| Current ratio | 16.71 | 23.72 | 18.23 | 14.08 | 12.39 | |
| Interest coverage | 19.16 | 11.08 | 0 | 0 | 0 | |
| Income quality | 0.94 | 1.08 | 0.72 | 0.9 | 0.58 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | -0.04 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 19.23 | 0 | 0 | -0.33 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.76 | 5.81 | 5.99 | 5.58 | 5.41 | |
| ROIC | -0.09 | -0.11 | -0.14 | -0.16 | -0.2 | |
| Return on tangible assets | -0.08 | -0.1 | -0.13 | -0.14 | -0.18 | |
| Graham Net | 4.45 | 3.56 | 3.21 | 2.76 | 2.47 | |
| Working capital | 168.75M | 154.48M | 138.78M | 123.02M | 105.53M | |
| Tangible asset value | 169.32M | 155.2M | 139.26M | 123.58M | 106.18M | |
| Net current asset value | 168.38M | 154.16M | 138.52M | 122.81M | 105.35M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 971K | 948K | 735.5K | 576.5K | 720K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 2.57K | 1.8K | 1.63K | 1.13K | 2.44K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.04 | 0.05 | 0.06 | 0.08 | 0.04 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.09 | -0.1 | -0.13 | -0.15 | -0.19 | |
| Capex per share | 0 | 0.02 | 0 | 0 | 0 |
RLYB Frequently Asked Questions
What is Rallybio Corporation stock symbol ?
Rallybio Corporation is a US stock , located in New haven of Ct and trading under the symbol RLYB
What is Rallybio Corporation stock quote today ?
Rallybio Corporation stock price is $1.73 today.
Is Rallybio Corporation stock public?
Yes, Rallybio Corporation is a publicly traded company.
Company Profile
- Volume Average 1.55M
- Market Capitalization 83.19M
- Employee 43
- CEO Dr. Stephen Uden M.B, M.D.
- Headquarters New Haven,CT,US
- IPO Date 2021-07-29
-
Website
https://www.rallybio.com 
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
